Literature DB >> 25787084

Influence of pulmonary hypertension on survival in advanced lung disease.

Don Hayes1, Sylvester M Black, Joseph D Tobias, Heidi M Mansour, Bryan A Whitson.   

Abstract

BACKGROUND: Effects of pulmonary hypertension (PH) in advanced lung disease remain unclear.
METHODS: The United Network for Organ Sharing database was queried from 1987 to 2013 to assess survival lung transplant candidates to determine influence of PH in advanced lung disease. Thresholds included mean pulmonary artery pressure ≥ 25 mmHg (mild PH) and 35 mmHg (severe PH).
RESULTS: Of 12,405 listed possible candidates, 10,158 were used for univariate analysis, 7050 for Kaplan-Meier (KM) function, 6196 for multivariate Cox models, and 5328 (mild PH) and 1910 (severe PH) for propensity score matching (PSM). For mild and severe PH, univariate revealed that PH was associated with survival difference (HR = 1.530, 95% CI 1.416, 1.654, p < 0.001) and (HR = 2.033, 95% CI 1.851, 2.232, p < 0.001), respectively. KM function curves demonstrated a significant difference for mild PH (Log-rank test: Chi square (df = 1): 117.76, p < 0.0001) and severe PH (Log-rank test: Chi square (df = 1): 230.91, p < 0.0001). Multivariate Cox models also found a significant increased risk for death for mild PH (HR = 1.750, 95% CI 1.606, 1.907, p < 0.001) and severe PH (HR = 2.088, 95% CI 1.879, 2.319, p < 0.001). PSM confirmed this increased risk for death for mild PH (HR = 1.695, 95% CI 1.502, 1.914, p < 0.001) and severe PH (HR = 1.976, 95% CI 1.641, 2.379, p < 0.001).
CONCLUSIONS: PH is associated with significant increased risk for death in patients with advanced lung disease.

Entities:  

Mesh:

Year:  2015        PMID: 25787084     DOI: 10.1007/s00408-015-9696-8

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  36 in total

1.  THE INFLUENCE OF HYDROGEN ION CONCENTRATION AND HYPOXIA ON THE PULMONARY CIRCULATION.

Authors:  Y ENSON; C GIUNTINI; M L LEWIS; T Q MORRIS; M I FERRER; R M HARVEY
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

Review 3.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

4.  Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease.

Authors:  Charlotte U Andersen; Søren Mellemkjær; Jens Erik Nielsen-Kudsk; Elisabeth Bendstrup; Ulf Simonsen; Ole Hilberg
Journal:  Respir Med       Date:  2012-09-30       Impact factor: 3.415

5.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

6.  Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival.

Authors:  Adriano R Tonelli; Sebastian Fernandez-Bussy; Saba Lodhi; Olufemi A Akindipe; Robin D Carrie; Karen Hamilton; Kamal Mubarak; Maher A Baz
Journal:  J Heart Lung Transplant       Date:  2010-05-13       Impact factor: 10.247

7.  Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.

Authors:  Motohiro Kimura; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Hiromichi Aso; Koji Sakamoto; Yoshinori Hasegawa
Journal:  Respiration       Date:  2012-12-19       Impact factor: 3.580

8.  Pulmonary hypertension is associated with higher mortality in cystic fibrosis patients awaiting lung transplantation.

Authors:  F Venuta; A R Tonelli; M Anile; D Diso; T De Giacomo; F Ruberto; E Russo; M Rolla; S Quattrucci; E A Rendina; N Li Phd; G F Coloni
Journal:  J Cardiovasc Surg (Torino)       Date:  2012-12       Impact factor: 1.888

9.  Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Jørn Carlsen; Kasper Hasseriis Andersen; Søren Boesgaard; Martin Iversen; Daniel Steinbrüchel; Claus Bøgelund Andersen
Journal:  J Heart Lung Transplant       Date:  2012-12-21       Impact factor: 10.247

10.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

Authors:  A F Shorr; J L Wainright; C S Cors; C J Lettieri; S D Nathan
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

View more
  5 in total

1.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

2.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy.

Authors:  Maria F Acosta; Priya Muralidharan; Carissa L Grijalva; Michael D Abrahamson; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

4.  A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease.

Authors:  Simon Bax; Charlene Bredy; Aleksander Kempny; Konstantinos Dimopoulos; Anand Devaraj; Simon Walsh; Joseph Jacob; Arjun Nair; Maria Kokosi; Gregory Keir; Vasileios Kouranos; Peter M George; Colm McCabe; Michael Wilde; Athol Wells; Wei Li; Stephen John Wort; Laura C Price
Journal:  ERJ Open Res       Date:  2018-05-04

5.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.